Cochrane Review Of HCV Drugs - The Controversy Continues

Cochrane Review Of HCV Drugs - The Controversy Continues - Hallo friendsTHE LEK NEWS, In the article you read this time with the title Cochrane Review Of HCV Drugs - The Controversy Continues, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : Cochrane Review Of HCV Drugs - The Controversy Continues
link : Cochrane Review Of HCV Drugs - The Controversy Continues

Read too


Cochrane Review Of HCV Drugs - The Controversy Continues

The Backstory
In the summer of 2017 a Cochrane Review concluded that achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits; reduce risks for HCV-related morbidity or all-cause mortality. Later that year, as we entered into November, Cochrane group’s conclusions changed, somewhat. Check out a quick overview, here.

Twitter & Mr. Chang
Henry E. Chang provided this blog with the above mentioned links, and kept the HCV community updated throughout the ongoing controversy by documenting each rebuttal on twitter, here is nice collection of his tweets: "Reactions from Hepatitis C Community on a Recent Cochrane Review of DAAs."

The Controversy Continues
On Twitter today an update from @HenryEChang

The Front Lines Of The Hepatitis C Crises
Patients, advocates, and physicians who have been on the front lines of the hepatitis C crises (for decades) understand first hand the damage Cochrane group’s irresponsible conclusions caused individuals living with HCV.

The Long Road To Safe And Effective HCV Drugs
Like many of you, I have closely followed the long road to safe and effective HCV drugs. Even experienced the pain HCV has on families, including my own. Today, as I review emails from people who are either treating HCV, or have questions about treatment, I can't help but remember those early emails back in 2000, when my own journey began. Many were tragic; a spouse asking about cirrhosis, a mother with liver cancer, a husband just received a liver transplant, or the unthinkable, a loved one didn't make it. Slowly, over a span of 15 years, those odds changed with the FDA approval of effective agents, today most emails are about cost and coverage. Finally, people are getting treated, reaching SVR, the tide has turned.

The Damage Is Done
Soon after the Cochrane Review was published, patients were hit with this horrendous headline in the media; "Hepatitis ‘wonder drug’ may be clinically ineffective, say experts." Leaving innocent patients confused and frightened, we'll never know how many people decided to forgo testing or treatment that summer, we can only surmise.

The New Era Of Hepatitis C Drugs
Today we have effective drugs to cure HCV, across all six HCV genotypes, including direct-acting antiviral therapy for people with severe liver damage, such as compensated cirrhosis, or kidney disease. HCV eradication is associated with the reversal of fibrosis, improvement of fibrosis and quality of life, as well as overall reduction of liver cancer, liver failure, risk of liver transplant, and liver-related mortality, including extrahepatic manifestations of HCV in patients who achieve SVR.

Do you think those Cochrane people, authors, men or women, even know the damaged they have caused?

I do, and I am not alone.

Stay aware, stay healthy.
Tina


Thus Article Cochrane Review Of HCV Drugs - The Controversy Continues

That's an article Cochrane Review Of HCV Drugs - The Controversy Continues This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Cochrane Review Of HCV Drugs - The Controversy Continues with the link address https://theleknews.blogspot.com/2018/03/cochrane-review-of-hcv-drugs.html

Subscribe to receive free email updates:

0 Response to "Cochrane Review Of HCV Drugs - The Controversy Continues"

Post a Comment